AGMB

AgomAb Therapeutics · USD

Market closed US (NYSE / Nasdaq) · 09:30–16:00 · Mon 20:53 · approx

Deep AI analysis (big model)

No deep analysis yet. Portfolio holdings are analysed automatically; for any other stock, click “Request deep AI analysis” above.

About AgomAb Therapeutics

AgomAb Therapeutics (AGMB) is a biotechnology company focused on developing antibody-based therapies for various diseases, operating within the Healthcare sector.

HealthcareBiotechnologyPharmaceuticals

Ticker	AGMB
Name	AgomAb Therapeutics
Currency	USD
Sector	Healthcare

Reputation

😎

How liked 50/100

From 0 recent analysed stories — 0 good · 0 bad · 0 neutral. Trend: stable.

Reputation builds as news about this company is analysed.

Price history & forecast

30-day forecast — Linear regression, Holt's exponential smoothing, and drift, plus a news-adjusted consensus (sentiment tilt +0.00). Estimates only, not advice.

Candlestick, volume & news sentiment

…

good bad neutral closed

Open/high/low/close candles with volume beneath; hover for OHLC, change and volume. Dots mark analysed news by sentiment; shaded bands are when the market was closed. Day and Week show intraday detail; Month+ show daily candles. Step through time with ‹ ›.

Forecast accuracy (backtested)

No scored forecasts yet. Every visit records the day's forecast; once those predicted dates pass, this table fills in with how each method actually did (1 snapshot(s) recorded so far, none matured yet).

Technical analysis

BEARISH

36.95

RSI (14)i

10.68

SMA 20i

10.91

SMA 50i

—

SMA 200i

6.34%

1di

12.86%

1wi

-2.27%

1mi

4.74%

30d voli

16.21

52w highi

9.13

52w lowi

-36.40%

from highi

-0.44

MACDi

MACD bearish crossover

Computed from 90 locally-stored price bars.

AI signals

HOLD 70% · long_term 2026-06-08 10:41

The stock has been in a downtrend with significant losses over the past week, and there are no recent positive news to counterbalance this negative momentum. The price is near its lowest point of the window period, suggesting continued caution until more positive developments emerge.

qwen2.5:3b